Department of Endocrinology, Diabetology and Internal Diseases, Medical University of Bialystok, Bialystok, Poland.
Horm Metab Res. 2012 Dec;44(13):957-61. doi: 10.1055/s-0032-1316352. Epub 2012 Jun 29.
The aim of the study was to assess the usefulness of circulating chemokines CXCL9 and CXCL10 measurements as surrogate markers of GO activity and as a guideline in therapeutic decision-making. Forty-two individuals were divided into 4 groups: 1. 15 euthyroid patients with clinical symptoms of orbitopathy (GO) who underwent corticosteroid therapy consisting of intravenous infusions of methylprednisolone (MP) and teleradiotherapy (TR); 2. 10 patients with hyperthyroid GD (Gtx); 3. 10 patients with GD in euthyreosis (Geu); and 4. 7 healthy volunteers age and sex-matched to groups 1-3. The serum samples were collected 24 h before MP, 24 h after first dose of MP, before TR and at the end of therapy. Serum CXCL9 and CXCL10 were determined by ELISA and TSH-Rab by RIA. There were significant reductions in CXCL9 and CXCL10 serum concentrations during CS and TR treatment as compared both to control group and to basal values in GO patients. Moreover, CXCL9 concentration was significantly diminished in comparison to controls in GO patients who were identified later as corticosteroid-respondent (p<0.001). In this latter group of patients, CXCL9 was also found to be significantly reduced 24 h after first dose of MP as compared to non-respondents (p<0.02). The high-degree positive correlation between CXCL9 and CXCL10 was found (R=0.8; p<0.001). Our results suggest that the increased concentrations of CXCL9 (and CXCL10), at least in part, reflect the activity of orbital inflammation and therefore these chemokines could serve as a guideline in therapeutic decision-making in patients with Graves' orbitopathy.
本研究旨在评估循环趋化因子 CXCL9 和 CXCL10 测量作为 GO 活动的替代标志物的有用性，并作为治疗决策的指南。42 名个体分为 4 组：1. 15 名患有眼眶病（GO）临床症状的甲状腺功能正常患者，接受皮质类固醇治疗，包括甲基强的松龙（MP）静脉输注和远程放射治疗（TR）；2. 10 名甲状腺功能亢进型 GD（Gtx）患者；3. 10 名甲状腺功能正常的 GD 患者（Geu）；4. 7 名年龄和性别与 1-3 组匹配的健康志愿者。采集 MP 前 24 小时、MP 首剂量后 24 小时、TR 前和治疗结束时的血清样本。通过 ELISA 测定血清 CXCL9 和 CXCL10，通过 RIA 测定 TSH-Rab。与对照组和 GO 患者基础值相比，CS 和 TR 治疗期间血清 CXCL9 和 CXCL10 浓度均显著降低。此外，在被确定为皮质类固醇反应者的 GO 患者中，与对照组相比，CXCL9 浓度也显著降低（p<0.001）。在后者组患者中，与非反应者相比，MP 首剂量后 24 小时 CXCL9 也显著降低（p<0.02）。发现 CXCL9 与 CXCL10 之间存在高度正相关（R=0.8；p<0.001）。我们的结果表明，CXCL9（和 CXCL10）浓度的增加至少部分反映了眼眶炎症的活动，因此这些趋化因子可以作为 Graves 眼病患者治疗决策的指南。
